Diffusion Pharmaceuticals is a clinical stage biotechnology company focused on extending the life expectancy of cancer patients by improving the effectiveness of current standard of care treatments including radiation therapy and chemotherapy. Diffusion is developing its lead drug, trans sodium crocetinate TSC , for use in the many cancer types in which tumor hypoxia oxygen deprivation is known to diminish the effectiveness of current treatments. TSC targets the cancer s hypoxic micro environment, re oxygenating treatment resistant tissue and making the cancer cells more vulnerable to the therapeutic effects of treatments such as radiation therapy and chemotherapy, without the apparent addition of any serious side effects. TSC has potential application in other indications involving hypoxia, such as stroke and neurodegenerative diseases. A Phase II clinical program, completed in the second quarter of , evaluated patients with newly diagnosed glioblastoma multiforme GBM . The study demonstrated a favorable safety and efficacy profile for TSC combined with standard of care. This trial has been the basis for discussions with the U.S. Food and Drug Administration. A Phase III program in newly diagnosed GBM is being planned. Additional planned studies include a Phase II/III trial in pancreatic cancer. TSC s novel mechanism safely re oxygenates a range of tumor types, so its therapeutic potential is not limited to specific tumors, thereby making it potentially useful to improve current standard of care treatments of many life threatening cancers.
Quote | Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN)
Last: | $4.40 |
---|---|
Change Percent: | -7.36% |
Open: | $4.23 |
Close: | $4.40 |
High: | $5.19 |
Low: | $4.165 |
Volume: | 349,534 |
Last Trade Date Time: | 08/16/2023 03:00:00 am |
News | Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN)
2023-08-16 13:38:03 ET Gainers: EBET ( EBET ) +160% . Novo Integrated Sciences ( NVOS ) +71% . Tivic Health Systems ( TIVC ) +58% . WeTrade Group ( WETG ) +43%. DLocal Limited ( DLO ) +35% . JX Luxventure Limited ( JXJT )...
Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) is one of today's top gainers. The company's shares are currently up 15.2% on the day to $4.6. Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product...
Message Board Posts | Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN)
Subject | By | Source | When |
---|---|---|---|
So am I wrong that this is now | BooDog | investorshub | 11/18/2022 3:15:46 PM |
Just saw this is having a proxy battle. | BooDog | investorshub | 11/18/2022 12:38:55 PM |
whytestocks: $DFFN News Article - Diffusion Pharmaceuticals Reports Third Quarter 2022 Financial Res | whytestocks | investorshangout | 11/14/2022 9:05:53 PM |
I agree that this has potential. | boston127 | investorshub | 04/23/2022 8:20:04 AM |
2Mill o/s w/ topline data coming anytime -> | stock1ace1 | investorshub | 04/21/2022 11:37:18 PM |
News, Short Squeeze, Breakout and More Instantly...
Diffusion Pharmaceuticals Inc. Company Name:
DFFN Stock Symbol:
NASDAQ Market:
Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) is one of today's top gainers. The company's shares are currently up 15.2% on the day to $4.6. Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product...
Approximately 71% of Stockholders Voted in Favor of the Transaction Diffusion Announces 1-for-1.5 Reverse Stock Split Merger on Track to Close on August 16, 2023 CHARLOTTESVILLE, Va., Aug. 15, 2023 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) today announced...
NEW YORK, NY / ACCESSWIRE / April 14, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Univar Solutions Inc. (NYSE:UNVR)'s ...